SCHEMBL1916481

SCHEMBL1916481

CCCCCCCCCCCCCCC(O)(O)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 8/20 0.48
GGPS1 O95749 5/20 0.48
CES2 O00748 1/20 0.47
PPARG P37231 4/20 0.46
PPARD Q03181 4/20 0.46
PPARA Q07869 4/20 0.46
TSHR P16473 3/20 0.46
GPR84 Q9NQS5 3/20 0.46
HDAC11 Q96DB2 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
TLR2 O60603 1/20 0.46
MEN1 O00255 1/20 0.46
ESR1 P03372 1/20 0.46
FABP4 P15090 1/20 0.46
ALOX15 P16050 1/20 0.46
PTPN1 P18031 1/20 0.46
PDE4A P27815 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6056806 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL327410 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL6056786 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL6056853 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL6056832 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL6056892 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL7172854 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL1990820 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL6056814 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD
SCHEMBL6056817 1.00 FDPS (0.48) FDPSGGPS1CES2PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11929171-B2 Methods for evaluation and treatment of glycemic dysregulation and atherosclerotic cardiovascular disease and applications thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-03-12 US claimed
US-11112717-B2 Electrostatic ink compositions and scratch-off structures HP INDIGO B.V. (NL) 2021-09-07 US claimed
US-20200227166-A1 Methods for Evaluation and Treatment of Glycemic Dysregulation and Atherosclerotic Cardiovascular Disease and Applications Thereof THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-07-16 US claimed
EP-3039064-A1 EXTRACTION METHOD OF A POLYESTER POLYMER OR CUTIN FROM THE WASTED TOMATO PEELS AND POLYESTER POLIMER SO EXTRACTED Chiesa, Virginio (IT) 2016-07-06 EP claimed
WO-2015028299-A1 EXTRACTION METHOD OF A POLYESTER POLYMER OR CUTIN FROM THE WASTED TOMATO PEELS AND POLYESTER POLIMER SO EXTRACTED CHIESA, Virginio (IT) 2015-03-05 WO claimed
US-20250188245-A1 TEREPHTHALIC ACID ESTERS FORMATION 9449710 CANADA INC (CA) 2025-06-12 US disclosed
EP-4541783-A2 TEREPHTHALIC ACID ESTERS FORMATION 9449710 Canada Inc. (CA) 2025-04-23 EP disclosed
US-12263489-B2 Manufacturing method of the operation pipe SHIMADZU CORPORATION (JP) 2025-04-01 US disclosed
WO-2025062180-A1 SYSTEMS, METHODS, AND COMPOSITIONS FOR UPCYCLING POLYESTERS 9449710 CANADA INC. (CA) 2025-03-27 WO disclosed
EP-3681854-B1 TEREPHTHALIC ACID ESTERS FORMATION 9449710 CANADA INC (CA) 2025-01-29 EP disclosed
CN-119144542-A Ornamental peach petal nano vesicle and preparation method and application thereof 常德职业技术学院 2024-12-17 CN disclosed
CN-118834249-A Resin glycoside compound, preparation method and application thereof 中国科学院上海药物研究所 2024-10-25 CN disclosed
US-20010048964-A1 Low calorie fat compositions MONSANTO TECHNOLOGY, LLC 2001-12-06 US disclosed
WO-2001076387-A2 LOW CALORIE FAT COMPOSITIONS MONSANTO TECHNOLOGY LLP (US) 2001-10-18 WO disclosed
WO-2001060172-A1 LOW CALORIE FAT COMPOSITIONS MONSANTO TECHNOLOGY LLC (US) 2001-08-23 WO disclosed
US-5919434-A ENCAPSULATED GAS MICROBUBBLES NYCOMED IMAGING AS (NO) 1999-07-06 US disclosed
EP-0409320-B1 Process for the isolation of hydroxy fatty acid derivatives from convolvulaceae plants QUEST INT (NL) 1994-10-05 EP disclosed
US-5296621-A Extracting plants with organic solvent, desolventizing extract, dispersing in water, hydrolyzing UNILEVER PATENT HOLDINGS B.V. (NL) 1994-03-22 US disclosed
EP-0409320-A2 Process for the isolation of hydroxy fatty acid derivatives from convolvulaceae plants QUEST INTERNATIONAL B.V. (NL) 1991-01-23 EP disclosed
EP-0371568-A1 Process for producing gamma-lactones UNILEVER N.V. (NL) 1990-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188245-A1 TEREPHTHALIC ACID ESTERS FORMATION DGAT2, DGAT1, SLC16A3 FDPS 409/4885GGPS1 1118/4885CES2 183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.